close
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Processa Pharmaceuticals, Inc. - Common Stock (NQ:PCSA)

0.3890 +0.0345 (+9.73%)
Streaming Delayed Price Updated: 4:00 PM EDT, Oct 31, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Processa Pharmaceuticals, Inc. - Common Stock

< Previous 1 2 3 4 5 6 7 8 9 10 Next >
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Presents New Data from NGC-Cap Phase 1b Trial at AACR Annual Meeting
Via Investor Brand Network
12 Health Care Stocks Moving In Monday's After-Market Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
How Is The Market Feeling About Processa Pharma?
 
Via Benzinga
BioMedNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at Upcoming MedInvest Conference
Via Investor Brand Network
TinyGemsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at Upcoming MedInvest Conference
Via Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Announces Participation at American Association for Cancer Research Annual Meeting
Via Investor Brand Network
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) to Present at 2024 BIO CEO & Investor Conference
Via Investor Brand Network
Processa Pharmaceuticals And 2 Other Penny Stocks Insiders Are Buying
The Dow Jones index closed higher by around 150 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and... 
Via Benzinga
Topics Stocks
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Closes on $7M Public Offering
Via Investor Brand Network
Expensify And 3 Other Stocks Under $3 Insiders Are Buying
The Dow Jones index closed higher by more than 350 points on Thursday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and... 
Via Benzinga
Topics Stocks
Relmada Therapeutics And 2 Other Penny Stocks Insiders Are Buying
The Dow Jones index closed lower by more than 300 points on Wednesday. When insiders purchase or sell shares, it indicates their confidence or concern around the company's prospects. Investors and... 
Via Benzinga
Topics Stocks
Nasdaq Stocks Above $2 to Watch Now! LVTX, INBS, IKT, PCSA, DYAI
Via AB Newswire
Topics Retirement
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Monday
It's time to start the trading week with a dive into the biggest pre-market stock movers worth watching on Monday morning! 
Via InvestorPlace
Nasdaq Down Over 50 Points; Colgate-Palmolive Posts Upbeat Results
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite falling over 50 points on Friday The Dow traded up 0.05% to 38,069.66 while the NASDAQ fell 0.4% to 15,447.78. The S&P 500... 
Via Benzinga
Topics Stocks
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Releases Pricing Information for $7M Public Offering
Via Investor Brand Network
Why Intel Shares Are Trading Lower By Over 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
Shares of Intel Corporation (NASDAQ: INTC) fell sharply during Friday’s session. Intel reported upbeat results for its fourth quarter, but issued a weak forecast for the first quarter. 
Via Benzinga
12 Health Care Stocks Moving In Friday's Intraday Session
 
Via Benzinga
Crude Oil Down 1%; American Express Shares Rise After Q4 Results
U.S. stocks traded higher midway through trading, with the Dow Jones index gaining over 100 points on Friday. The Dow traded up 0.32% to 38,170.95 while the NASDAQ rose 0.10% to 15,525.24. The S&P 500... 
Via Benzinga
Topics Stocks
What's Going On With Anti Cancer Focused Processa Pharmaceuticals Stock Today?
Processa Pharmaceuticals stock surge - 148.8% gain to $5.10 post Next Generation Capecitabine (NGC-Cap) Phase 1b success. 
Via Benzinga
Processa Pharmaceuticals Announces Pricing of $7.0 Million Public Offering
From Processa Pharmaceuticals, Inc.
Via GlobeNewswire
Intel, Nvidia, AMD, Processa Pharmaceuticals, Tesla: Why These 5 Stocks Are On Investors' Radars Today
 
Via Benzinga
12 Health Care Stocks Moving In Thursday's After-Market Session
 
Via Benzinga
Nasdaq Edges Lower; American Airlines Posts Upbeat Earnings
U.S. stocks traded mixed toward the end of trading, with the Nasdaq Composite turning lower on Thursday. The Dow traded up 0.25% to 37,900.45 while the NASDAQ fell 0.13% to 15,462.53. The S&P 500 also... 
Via Benzinga
Topics Stocks
Why Is Processa Therapeutics (PCSA) Stock Up 90% Today?
Processa Pharmaceuticals successfully completed its safety trial for a key cancer drug. Now, PCSA stock is soaring on the positive implications. 
Via InvestorPlace
Crude Oil Rises 2%; Tesla Shares Plunge After Downbeat Results
U.S. stocks traded slightly higher midway through trading, with the Nasdaq Composite gaining around 0.2% on Thursday. The Dow traded up 0.06% to 37,829.32 while the NASDAQ rose 0.22% to 15,515.62. The... 
Via Benzinga
Topics Stocks
Why Humana Shares Are Trading Lower By Over 11%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
Shares of Humana Inc. (NYSE: HUM) fell sharply during Thursday’s session after the company reported fourth-quarter FY23 earnings and issued 2024 guidance. 
Via Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
 
Via Benzinga
InvestorNewsBreaks – Processa Pharmaceuticals Inc. (NASDAQ: PCSA) Completes Phase 1b Safety Evaluation of NGC-Cap
Via Investor Brand Network
< Previous 1 2 3 4 5 6 7 8 9 10 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.

Starting at $3.75/week.

Subscribe Today